Can Checkpoint Inhibitors Jump-Start Glioblastoma Drug Development?
Executive Summary
The recent failure of Celldex’s vaccine Rintega was disappointing, but that has not dampened researchers’ enthusiasm for immunotherapy in the high-risk, high-reward glioblastoma field.
You may also be interested in...
IDO Emerges As Clean Combo Partner, Rising Star At AACR
Clean safety profile for combination of IDO inhibitors with anti-PD-1 agents in early studies presented at the American Association for Cancer Research meeting contrasts with the toxicity-laden CTLA-4/PD-1 regimen in Bristol's Phase III CheckMate 067 study.
What To Look Out For In Glioblastoma At ASCO
Bristol-Myers Squibb, Tracon Pharmaceuticals and Ziopharm are slated to present promising early data in glioblastoma at upcoming ASCO meeting.
Avastin QoL Data In First-Line Glioblastoma Muddy Expansion Plans
Genentech’s bevacizumab was associated with improved maintenance of baseline quality of life and performance status in a confirmatory trial conducted under accelerated approval, but an NCI-funded study found higher rates of neurocognitive decline, increased symptom severity and decline in health-related quality of life.